Immunogenic plasmodium falciparum antigen compositions and uses thereof
AssigneeThe Regents of the University of California
InventorsPhilip L. Felgner, Xiaowu Liang, Robert Sauerwein
Life of this patent
Estimating the term…
Abstract
Contemplated compositions and methods employ selected antigens form Plasmodium falciparum and can be used as a vaccine, therapeutic agent, and/or diagnostic tool. Especially preferred antigens are post-challenge immunity associated antigens that are identified via pre-infection suppressive treatment, controlled sub-symptomatic infection to develop immunity, and comparative proteomic differential analysis.
Claims21
An antigenic composition comprising:
- a plurality of at least partially purified post-challenge immunity associated antigens of Plasmodium falciparum;
- wherein the plurality of post-challenge immunity associated antigens comprise at least three antigens selected from the group consisting of:
- an LSA-1 or an immunogenic fragment thereof, a CSP or an immunogenic fragment thereof, a MSP4 or an immunogenic fragment thereof, and a SET domain protein or an immunogenic fragment thereof;
- and
- a carrier associated with the plurality of post-challenge immunity associated antigens.
A method of developing a multivalent vaccine formulation that confers persistent immunity against Plasmodium falciparum, comprising:
- identifying a plurality of post-challenge immunity associated antigens of Plasmodium falciparum;
- at least partially purifying each of the post-challenge immunity associated antigens;
- and
- including the plurality of at least partially purified post-challenge immunity associated antigens into a vaccine formulation comprising a pharmaceutically acceptable carrier and optionally an adjuvant.
A method for assessing the immune competence of an individual to a Plasmodium falciparum, comprising:
- administering a plurality of post-challenge immunity associated antigens of the Plasmodium falciparum to the individual;
- obtaining a blood sample from the individual;
- determining and Quantifying the amount of of antibodies against each of the plurality of post-challenge immunity associated antigens in the blood sample, and comparing the determined quantities of antibodies against a respective threshold value of antibodies against the same plurality of post-challenge immunity associated antigens;
- wherein the respective threshold value of antibodies is based on a plurality of individuals that have persistent and effective immunity against the Plasmodium falciparum, and the quantities of antibodies above the respective threshold value is indicative of immunity to the Plasmodium falciparum.
(canceled)
Dependencies are inferred from the claim text.